KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Treasury Shares (2016 - 2025)

Ionis Pharmaceuticals has reported Treasury Shares over the past 14 years, most recently at $473000.0 for Q4 2025.

  • Quarterly results put Treasury Shares at $473000.0 for Q4 2025, up 54.07% from a year ago — trailing twelve months through Dec 2025 was $473000.0 (up 54.07% YoY), and the annual figure for FY2025 was $473000.0, up 54.07%.
  • Treasury Shares for Q4 2025 was $473000.0 at Ionis Pharmaceuticals, up from $307000.0 in the prior quarter.
  • Over the last five years, Treasury Shares for IONS hit a ceiling of $2.6 million in Q4 2021 and a floor of $143000.0 in Q4 2022.
  • Median Treasury Shares over the past 5 years was $307000.0 (2024), compared with a mean of $753400.0.
  • Biggest five-year swings in Treasury Shares: tumbled 94.54% in 2022 and later soared 58.04% in 2023.
  • Ionis Pharmaceuticals' Treasury Shares stood at $2.6 million in 2021, then tumbled by 94.54% to $143000.0 in 2022, then soared by 58.04% to $226000.0 in 2023, then skyrocketed by 35.84% to $307000.0 in 2024, then soared by 54.07% to $473000.0 in 2025.
  • The last three reported values for Treasury Shares were $473000.0 (Q4 2025), $307000.0 (Q4 2024), and $226000.0 (Q4 2023) per Business Quant data.